WO2012153312A1 - Process for the purification of pioglitazone - Google Patents

Process for the purification of pioglitazone Download PDF

Info

Publication number
WO2012153312A1
WO2012153312A1 PCT/IB2012/052370 IB2012052370W WO2012153312A1 WO 2012153312 A1 WO2012153312 A1 WO 2012153312A1 IB 2012052370 W IB2012052370 W IB 2012052370W WO 2012153312 A1 WO2012153312 A1 WO 2012153312A1
Authority
WO
WIPO (PCT)
Prior art keywords
pioglitazone
dhp
solution
dimethylformamide
mixture
Prior art date
Application number
PCT/IB2012/052370
Other languages
French (fr)
Inventor
Mohammed Salman Hashmi
Murad Ismail INAMDAR
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2012153312A1 publication Critical patent/WO2012153312A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention provides an improved process for the preparation of pioglitazone which is substantially free of dehydropioglitazone impurity.
  • Pioglitazone of Formula I chemically ( ⁇ )-5-[[4-[2-(5-ethyl-2- pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, is used as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes (non-insulin- dependent diabetes mellitus or "NIDDM").
  • NIDDM non-insulin- dependent diabetes mellitus
  • pioglitazone is its monohydrochloride salt.
  • Dehydropioglitazone (hereinafter referred to as "DHP” or “DHP of Formula II") is known as an intermediate in the synthesis of pioglitazone or salts thereof.
  • DHP is also present as a process impurity or degradation product in pioglitazone or salts thereof.
  • reasons are attributed for the generation of DHP in pioglitazone. Some factors linked to the generation of this impurity include the incomplete reduction of DHP and the oxidation of pioglitazone during isolation or while on stability.
  • U.S. Publication 2006/0252803 provides a process for the preparation of pioglitazone which involves dissolving DHP of Formula II in formic acid and hydrogenating with hydrogen in the presence of 10% Palladium on Carbon under 2 atmospheric pressures and a temperature of 80°C. This process reportedly provides pioglitazone having less than about 0.14 % of the impurity at RRT 0.64 (HPLC).
  • U.S. Publication 2009/118514 provides various purification methods for pioglitazone. It provides obtaining a solution of pioglitazone with a mixture of dimethylformamide (DMF) and 4% water, DMF and 5% methanol, DMF and 10% methanol, 1 ,4-dioxane or DMF and isopropyl alcohol at a temperature of about 90°C and precipitating pioglitazone from the solution by cooling to a temperature of about 25°C.
  • DMF dimethylformamide
  • U.S. Publication 2007/0078170 provides a process for the preparation of pioglitazone which involves obtaining a clear solution of pioglitazone in
  • dimethylformamide at 85°C and adding methanol at a temperature of 60°C and further cooling to 10°C to precipitate pioglitazone.
  • API active pharmaceutical ingredient
  • the purity of an API is critical for commercialization.
  • the product of a chemical reaction is rarely just the target compound.
  • Side products and by-products of the reaction and adjunct reagents used in the reaction will, in most cases, also be present in the product in varying amounts. Extra effort is often required to get pharmaceutically acceptable levels of purity of the target compound.
  • the present invention provides a process for the preparation of pioglitazone substantially free of DHP which comprises:
  • step b) treating the solution obtained in step a) with a mixture of acetone and
  • pioglitazone substantially free of DHP in the context of the present invention relates to pioglitazone having DHP in an amount of 0.1% or less, preferably 0.05% or less, more preferably 0.03% or less, most preferably undetectable as determined by HPLC analysis.
  • the pioglitazone may be prepared by any of the methods known in the art including those described in U.S. Patent Nos. 4,687,777; 5,585,495; 4,812,570; 5,554,758; 5,952,509 and 6, 100,403; U.S. Publication Nos. 2002/0106762 and 2002/0050563; WO 03/53367; WO 03/80056; WO 2004/07490; WO 2004/024059; WO 2004/101560 and WO 2004/101561.
  • the present invention provides a process for the preparation of pioglitazone substantially free of DHP which comprises:
  • step b) treating the solution obtained in step a) with a mixture of acetone and
  • the solution of pioglitazone in dimethylformamide may be obtained by treating pioglitazone or a salt thereof with dimethylformamide at a suitable temperature of 20°C to reflux under stirring.
  • the volume of dimethylformamide may be 3 to 10 times, preferably 4 to 7 times, to the weight of pioglitazone.
  • the solution of pioglitazone obtained in step a) can be optionally clarified to remove foreign particulate matter or treated with activated charcoal to remove coloring and other related impurities.
  • the solution of pioglitazone obtained in step a) may be optionally concentrated to reduce the amount of solvent.
  • Step b) treating the solution obtained in step a) with a mixture of antisolvent involves adding the solution of pioglitazone thereof obtained in step a) to a mixture of acetone and methanol or adding a mixture of acetone and methanol to the solution of pioglitazone obtained in step a) in optional order of succession at a temperature of about 65°C to about 75°C optionally under stirring. Preferably, it may be added at about 70°C to about 75 °C. The addition may be carried out dropwise for a time period of 15 minutes to 3 hours optionally under stirring.
  • the resultant mixture may be cooled to about 20°C to about 40°C in about 15 minutes to about 3 hours optionally under stirring.
  • it may to be cooled at about 30°C to about 35°C optionally under stirring.
  • the mixture of acetone and methanol can be taken in any ratio, preferably in 1 : 1 ratio.
  • the combined volume of the mixture of acetone and methanol may be about 5 times to about 15 times, preferably 7 to 12 times, more than the weight of pioglitazone.
  • the combined volume of acetone and methanol is about 20 ml (10 ml: 10 ml) for about 2 g of pioglitazone.
  • Step c) of isolating pioglitazone substantially free of DHP involves common isolation techniques such as one or more of washing, crystallization, precipitation, cooling, filtration, filtration under vacuum, decantation and centrifugation, or a combination thereof.
  • the isolated pioglitazone substantially free of DHP may be further dried at about 40°C to about 60°C under vacuum.
  • the pioglitazone obtained has a content of DHP in an amount of 0.05% or less.
  • the obtained purified pioglitazone can then be further converted into its pharmaceutically acceptable salts, preferably the hydrochloride salt, by any of the methods known in the art.
  • Dimethylformamide (10 mL) was heated to 80°C to 82°C and pioglitazone (2 g) was added to the hot solution and stirred at 80°C to get a clear solution.
  • the solution was cooled to 75 °C and mixture of acetone (10 mL) and methanol (10 mL) was added to the solution in 30 to 45 minutes at 70°C to 75°C. After complete addition, the reaction mass was cooled to 30°C to 35°C slowly in about 2 hours and was filtered. The solid was washed with dimethylformamide/acetone/methanol mixture (6 mL).
  • Dimethylformamide 200 mL was heated to 80°C to 85 °C and pioglitazone (40 g) was added to the hot solution and stirred at 80°C to get a clear solution.
  • the solution was cooled to 75°C and mixture of acetone (200 mL) and methanol (200 mL) was added to this solution in 30 minutes to 45 minutes at 65°C to 75°C. After complete addition, the reaction mass was cooled to 30°C to 35°C slowly in about 2 hours and was filtered. The solid was washed with acetone/methanol mixture (100 mL).
  • Dimethylformamide 25 mL was heated to 80°C to 85 °C and pioglitazone (5 g) was added at 85°C.
  • the solution was cooled to 55°C and a mixture of acetone (25 mL) and methanol (25 mL) was added to the solution in 30 minutes to 45 minutes at 55°C to 60°C.
  • the reaction mass was cooled to 35°C to 37°C slowly in about 2 hours and was filtered. The solid was washed with acetone/methanol mixture (10+lOmL).

Abstract

The present invention provides an efficient process for the purification of pioglitazone of Formula (I). It provides an improved purification for the preparation of pioglitazone substantially free of the DHP impurity of Formula (II).

Description

PROCESS FOR THE PURIFICATION OF PIOGLITAZONE
Field of the Invention
The present invention provides an improved process for the preparation of pioglitazone which is substantially free of dehydropioglitazone impurity.
Background of the Invention
Pioglitazone of Formula I, chemically (±)-5-[[4-[2-(5-ethyl-2- pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, is used as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes (non-insulin- dependent diabetes mellitus or "NIDDM").
The commercially available form of pioglitazone is its monohydrochloride salt.
Figure imgf000002_0001
Dehydropioglitazone (hereinafter referred to as "DHP" or "DHP of Formula II") is known as an intermediate in the synthesis of pioglitazone or salts thereof.
Figure imgf000002_0002
In addition, DHP is also present as a process impurity or degradation product in pioglitazone or salts thereof. Several reasons are attributed for the generation of DHP in pioglitazone. Some factors linked to the generation of this impurity include the incomplete reduction of DHP and the oxidation of pioglitazone during isolation or while on stability.
Several processes are known in the literature for making pioglitazone or a salt thereof, for example, U.S. Patent Nos. 4,687,777; 5,585,495; 4,812,570; 5,554,758; 5,952,509; and 6,100,403; U.S. Publications 2002/0106762 and 2002/0050563; WO 03/53367; WO 03/80056; WO 2004/07490; WO 2004/024059; WO 2004/101560; WO 2004/101561 , WO 2005/049610; WO 2008/075380; WO 2006/1 17654; WO
2008/142706; WO 2005/058827; WO 2009/104200; and WO 2009/133576.
U.S. Publication 2006/0252803 provides a process for the preparation of pioglitazone which involves dissolving DHP of Formula II in formic acid and hydrogenating with hydrogen in the presence of 10% Palladium on Carbon under 2 atmospheric pressures and a temperature of 80°C. This process reportedly provides pioglitazone having less than about 0.14 % of the impurity at RRT 0.64 (HPLC).
It also provides a process for the preparation of pioglitazone which involves combining DHP of Formula II with dimethylformamide and hydrogenating with hydrogen in the presence of Palladium on Carbon under 3 atmospheric pressures and a temperature of 50°C. It is reported that -68.5% of DHP was converted to pioglitazone, containing about 3.5 % impurities (HPLC).
U.S. Publication 2009/118514 provides various purification methods for pioglitazone. It provides obtaining a solution of pioglitazone with a mixture of dimethylformamide (DMF) and 4% water, DMF and 5% methanol, DMF and 10% methanol, 1 ,4-dioxane or DMF and isopropyl alcohol at a temperature of about 90°C and precipitating pioglitazone from the solution by cooling to a temperature of about 25°C.
U.S. Publication 2007/0078170 provides a process for the preparation of pioglitazone which involves obtaining a clear solution of pioglitazone in
dimethylformamide at 85°C and adding methanol at a temperature of 60°C and further cooling to 10°C to precipitate pioglitazone.
Impurities in pioglitazone or its hydrochloride salt, or any active pharmaceutical ingredient ("API"), are undesirable and, in extreme cases, might even be harmful to a patient being treated with a dosage form containing the API. The purity of an API is critical for commercialization. The product of a chemical reaction is rarely just the target compound. Side products and by-products of the reaction and adjunct reagents used in the reaction will, in most cases, also be present in the product in varying amounts. Extra effort is often required to get pharmaceutically acceptable levels of purity of the target compound.
As known by those skilled in the art, the management of process impurities is greatly enhanced by understanding their chemical structures and synthetic pathways and by identifying the parameters that influence the amount of impurities in the final product.
Extensive experimentation has been carried out by the present inventors to reduce the level of DHP in pioglitazone. As a result, the present inventors found an improved method for the preparation of pioglitazone substantially free of DHP by controlling the parameters such as solvents, time and temperature. The pioglitazone substantially free of DHP made by the process of the present invention is amenable for commercial scale.
Summary of the Invention
The present invention provides a process for the preparation of pioglitazone substantially free of DHP which comprises:
a) obtaining a solution of pioglitazone in dimethylformamide;
b) treating the solution obtained in step a) with a mixture of acetone and
methanol at a temperature of about 65°C to about 75°C; and
c) isolating pioglitazone substantially free of DHP.
Detailed Description of the Invention
The term "pioglitazone substantially free of DHP" in the context of the present invention relates to pioglitazone having DHP in an amount of 0.1% or less, preferably 0.05% or less, more preferably 0.03% or less, most preferably undetectable as determined by HPLC analysis.
The pioglitazone may be prepared by any of the methods known in the art including those described in U.S. Patent Nos. 4,687,777; 5,585,495; 4,812,570; 5,554,758; 5,952,509 and 6, 100,403; U.S. Publication Nos. 2002/0106762 and 2002/0050563; WO 03/53367; WO 03/80056; WO 2004/07490; WO 2004/024059; WO 2004/101560 and WO 2004/101561.
The present invention provides a process for the preparation of pioglitazone substantially free of DHP which comprises:
a) obtaining a solution of pioglitazone in dimethylformamide;
b) treating the solution obtained in step a) with a mixture of acetone and
methanol at a temperature of about 65°C to about 75°C; and
c) isolating pioglitazone substantially free of DHP.
The solution of pioglitazone in dimethylformamide may be obtained by treating pioglitazone or a salt thereof with dimethylformamide at a suitable temperature of 20°C to reflux under stirring.
The volume of dimethylformamide may be 3 to 10 times, preferably 4 to 7 times, to the weight of pioglitazone.
The solution of pioglitazone obtained in step a) can be optionally clarified to remove foreign particulate matter or treated with activated charcoal to remove coloring and other related impurities. The solution of pioglitazone obtained in step a) may be optionally concentrated to reduce the amount of solvent.
Step b), treating the solution obtained in step a) with a mixture of antisolvent involves adding the solution of pioglitazone thereof obtained in step a) to a mixture of acetone and methanol or adding a mixture of acetone and methanol to the solution of pioglitazone obtained in step a) in optional order of succession at a temperature of about 65°C to about 75°C optionally under stirring. Preferably, it may be added at about 70°C to about 75 °C. The addition may be carried out dropwise for a time period of 15 minutes to 3 hours optionally under stirring.
After the completion of addition, the resultant mixture may be cooled to about 20°C to about 40°C in about 15 minutes to about 3 hours optionally under stirring.
Preferably, it may to be cooled at about 30°C to about 35°C optionally under stirring.
The mixture of acetone and methanol can be taken in any ratio, preferably in 1 : 1 ratio. The combined volume of the mixture of acetone and methanol may be about 5 times to about 15 times, preferably 7 to 12 times, more than the weight of pioglitazone. For example, the combined volume of acetone and methanol is about 20 ml (10 ml: 10 ml) for about 2 g of pioglitazone.
Step c) of isolating pioglitazone substantially free of DHP involves common isolation techniques such as one or more of washing, crystallization, precipitation, cooling, filtration, filtration under vacuum, decantation and centrifugation, or a combination thereof.
The isolated pioglitazone substantially free of DHP may be further dried at about 40°C to about 60°C under vacuum. The pioglitazone obtained has a content of DHP in an amount of 0.05% or less.
The obtained purified pioglitazone can then be further converted into its pharmaceutically acceptable salts, preferably the hydrochloride salt, by any of the methods known in the art.
While the present invention has been described in terms of its specific
embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
EXAMPLES
Example 1 : Purification of Pioglitazone
Dimethylformamide (10 mL) was heated to 80°C to 82°C and pioglitazone (2 g) was added to the hot solution and stirred at 80°C to get a clear solution. The solution was cooled to 75 °C and mixture of acetone (10 mL) and methanol (10 mL) was added to the solution in 30 to 45 minutes at 70°C to 75°C. After complete addition, the reaction mass was cooled to 30°C to 35°C slowly in about 2 hours and was filtered. The solid was washed with dimethylformamide/acetone/methanol mixture (6 mL).
DHP impurity content after purification: 0.05%
DHP impurity content before purification: 0.16%
Yield: 90% Example 2: Purification of Pioglitazone
Dimethylformamide (200 mL) was heated to 80°C to 85 °C and pioglitazone (40 g) was added to the hot solution and stirred at 80°C to get a clear solution. The solution was cooled to 75°C and mixture of acetone (200 mL) and methanol (200 mL) was added to this solution in 30 minutes to 45 minutes at 65°C to 75°C. After complete addition, the reaction mass was cooled to 30°C to 35°C slowly in about 2 hours and was filtered. The solid was washed with acetone/methanol mixture (100 mL).
DHP impurity content after purification: 0.04%
DHP impurity content before purification: 0.15%
Yield: 92%
Example 3: Purification of Pioglitazone (Control)
Dimethylformamide (25 mL) was heated to 80°C to 85 °C and pioglitazone (5 g) was added at 85°C. The solution was cooled to 55°C and a mixture of acetone (25 mL) and methanol (25 mL) was added to the solution in 30 minutes to 45 minutes at 55°C to 60°C. After complete addition, the reaction mass was cooled to 35°C to 37°C slowly in about 2 hours and was filtered. The solid was washed with acetone/methanol mixture (10+lOmL).
DHP impurity content after purification: 0.11%
DHP impurity content before purification: 0.12%
Yield: 92%

Claims

We claim:
1) A process for preparing pioglitazone substantially free of DHP comprising the steps of:
a) obtaining a solution of pioglitazone in dimethylformamide; and
b) treating the solution obtained in step a) with a mixture of acetone and methanol at a temperature of about 65°C to about 75°C;
2) The process of claim 1, wherein the solution in step a) is obtained by treating pioglitazone or a salt thereof with dimethylformamide at a temperature of 20°C to reflux under stirring.
3) The process of claim 1, wherein the volume of dimethylformamide used for
preparing the solution in step a) is 3 to 10 times with respect to the weight of pioglitazone used.
4) The process of claim 3, wherein the volume of dimethylformamide is 4 to 7 times with respect to the weight of pioglitazone used.
5) The process of claim 1, wherein the acetone-methanol mixture is a 1 : 1 mixture. 6) The process of claim 1, wherein pioglitazone obtained contains 0.05% or less of DHP content as measured by HPLC.
7) The process of claim 1, further comprising the step of converting pioglitazone substantially free of DHP into its pharmaceutically acceptable salts.
8) The process of claim 7, wherein the pharmaceutically acceptable salt is the
hydrochloride salt.
PCT/IB2012/052370 2011-05-11 2012-05-11 Process for the purification of pioglitazone WO2012153312A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1385DE2011 2011-05-11
IN1385/DEL/2011 2011-05-11

Publications (1)

Publication Number Publication Date
WO2012153312A1 true WO2012153312A1 (en) 2012-11-15

Family

ID=46210328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/052370 WO2012153312A1 (en) 2011-05-11 2012-05-11 Process for the purification of pioglitazone

Country Status (1)

Country Link
WO (1) WO2012153312A1 (en)

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687777A (en) 1985-01-19 1987-08-18 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, useful as antidiabetic agents
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
US5554758A (en) 1991-03-25 1996-09-10 Takeda Chemical Industries, Ltd. Method for producing ethers
US5585495A (en) 1991-12-20 1996-12-17 The Upjohn Company Reduction method for substituted 5-methylene-thiazolidinediones
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US20020050563A1 (en) 1991-11-19 2002-05-02 Smithkline Beecham P.L.C. Process for the preparation of pharmaceutically active thiazolidine or oxazolidine compounds by a yeast reductase
US20020106762A1 (en) 1991-11-19 2002-08-08 Smith Kline Beecham Plc Process for the preparation of pharmaceutically active thiazolidine or oxazolidine compounds by a yeast reductase
WO2003053367A2 (en) 2001-12-20 2003-07-03 Teva Pharmaceutical Industries Ltd. Hydrogenation of precursors to thiazolidinedione antihyperglycemics
WO2003080056A2 (en) 2002-03-21 2003-10-02 Teva Pharmaceutical Industries Ltd. Fine particle size pioglitazone
WO2004007490A2 (en) 2002-07-16 2004-01-22 Cadila Healthcare Limited A process to prepare pioglitazone via several intermediates.
WO2004024059A2 (en) 2002-09-12 2004-03-25 Themis Laboratories Private Limited, Improved process for preparation of thiazolidinedione derivatives
WO2004101561A1 (en) 2003-05-13 2004-11-25 Synthon B.V. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
WO2004101560A1 (en) 2003-05-13 2004-11-25 Synthon B.V. Processes for making thiazolidinedione derivatives and compounds thereof
WO2005049610A1 (en) 2003-10-28 2005-06-02 Sandoz Ag Process for preparing thiazolidinediones
WO2005058827A1 (en) 2003-12-19 2005-06-30 Richter Gedeon Vegyészeti Gyár Rt. Process for the synthesis of pioglitazone hydrogen chloride
WO2006117654A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Processes for the preparation of pioglitazone or salts thereof
US20060252803A1 (en) 2001-12-20 2006-11-09 Ben-Zion Dolitzky Hydrogenation of precursors to thiazolidinedione antihyperglycemics
US20070078170A1 (en) 2003-08-28 2007-04-05 Khanduri Chandra H Process for the preparation of pioglitazone
WO2008075380A2 (en) 2006-12-21 2008-06-26 Ind-Swift Laboratories Limited Process for the preparation of thiazolidine derivatives
WO2008142706A2 (en) 2007-05-18 2008-11-27 Matrix Laboratories Ltd Novel process for the synthesis of pioglitazone and its salts thereof
US20090118514A1 (en) 2007-11-06 2009-05-07 Raghupathi Reddy Anumula Processes for preparing pioglitazone and its pharmaceutically acceptable salts
WO2009104200A1 (en) 2008-02-21 2009-08-27 Biocon Limited A method for preparation of thiazolidinedione derivatives
WO2009133576A1 (en) 2008-04-28 2009-11-05 Erregierre S.P.A. A process for the preparation of 4-[2-(5-ethyl-2-pyridyl)ethoxy]nitrobenzene and pioglitazone

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687777A (en) 1985-01-19 1987-08-18 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, useful as antidiabetic agents
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
US5554758A (en) 1991-03-25 1996-09-10 Takeda Chemical Industries, Ltd. Method for producing ethers
US20020050563A1 (en) 1991-11-19 2002-05-02 Smithkline Beecham P.L.C. Process for the preparation of pharmaceutically active thiazolidine or oxazolidine compounds by a yeast reductase
US20020106762A1 (en) 1991-11-19 2002-08-08 Smith Kline Beecham Plc Process for the preparation of pharmaceutically active thiazolidine or oxazolidine compounds by a yeast reductase
US5585495A (en) 1991-12-20 1996-12-17 The Upjohn Company Reduction method for substituted 5-methylene-thiazolidinediones
US6100403A (en) 1996-06-27 2000-08-08 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
WO2003053367A2 (en) 2001-12-20 2003-07-03 Teva Pharmaceutical Industries Ltd. Hydrogenation of precursors to thiazolidinedione antihyperglycemics
US20060252803A1 (en) 2001-12-20 2006-11-09 Ben-Zion Dolitzky Hydrogenation of precursors to thiazolidinedione antihyperglycemics
WO2003080056A2 (en) 2002-03-21 2003-10-02 Teva Pharmaceutical Industries Ltd. Fine particle size pioglitazone
WO2004007490A2 (en) 2002-07-16 2004-01-22 Cadila Healthcare Limited A process to prepare pioglitazone via several intermediates.
WO2004024059A2 (en) 2002-09-12 2004-03-25 Themis Laboratories Private Limited, Improved process for preparation of thiazolidinedione derivatives
WO2004101561A1 (en) 2003-05-13 2004-11-25 Synthon B.V. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
WO2004101560A1 (en) 2003-05-13 2004-11-25 Synthon B.V. Processes for making thiazolidinedione derivatives and compounds thereof
US20070078170A1 (en) 2003-08-28 2007-04-05 Khanduri Chandra H Process for the preparation of pioglitazone
WO2005049610A1 (en) 2003-10-28 2005-06-02 Sandoz Ag Process for preparing thiazolidinediones
WO2005058827A1 (en) 2003-12-19 2005-06-30 Richter Gedeon Vegyészeti Gyár Rt. Process for the synthesis of pioglitazone hydrogen chloride
WO2006117654A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Processes for the preparation of pioglitazone or salts thereof
WO2008075380A2 (en) 2006-12-21 2008-06-26 Ind-Swift Laboratories Limited Process for the preparation of thiazolidine derivatives
WO2008142706A2 (en) 2007-05-18 2008-11-27 Matrix Laboratories Ltd Novel process for the synthesis of pioglitazone and its salts thereof
US20090118514A1 (en) 2007-11-06 2009-05-07 Raghupathi Reddy Anumula Processes for preparing pioglitazone and its pharmaceutically acceptable salts
WO2009104200A1 (en) 2008-02-21 2009-08-27 Biocon Limited A method for preparation of thiazolidinedione derivatives
WO2009133576A1 (en) 2008-04-28 2009-11-05 Erregierre S.P.A. A process for the preparation of 4-[2-(5-ethyl-2-pyridyl)ethoxy]nitrobenzene and pioglitazone

Similar Documents

Publication Publication Date Title
EP2545049B1 (en) Crystalline salts of a potent hcv inhibitor
WO2011141933A2 (en) Process for preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts
WO2010056384A1 (en) Lenalidomide solvates and processes
WO2008061456A1 (en) The folacin-metformin compound and its manufacture
US9273010B2 (en) Process for bendamustine hydrochloride
JP2013531021A (en) Process for the preparation of crystal form II of febuxostat
US9783542B2 (en) Process for pralatrexate
CN107001276B (en) Sodium salt of uric acid transport protein inhibitor and crystal form thereof
CN1743316A (en) 2-substituted phenyl-4,4,5,5-tetramethyl-1,3,-dioxy imidazolines, their preparation and pharmaceutical use
WO2011031409A1 (en) Processes for preparing febuxostat
CN114890999B (en) Preparation method of PQQ
WO2012153312A1 (en) Process for the purification of pioglitazone
US9365526B2 (en) Process for the preparation of dasatinib and its intermediates
CN107531744B (en) Novel crystal form of obeticholic acid and preparation method thereof
EP2307399B1 (en) Process for controlling the growth of a raloxifene hydrochloride crystal
EP2079723B1 (en) Process for preparing anhydrous aripiprazole type i
KR20120129317A (en) Manufacturing Method Of Hetero Cyclic Compound
TW201228999A (en) Separation of triazine derivatives enantiomers using tartaric acid
JP5383123B2 (en) Method for producing pioglitazone hydrochloride
KR100881890B1 (en) Process for preparation of Sarpogrelate HCl salt
CA2722818A1 (en) Preparation of 1,7´-dimethyl-2´-propyl-2,5´-bi-1h-benzimidazole
EP1720867A2 (en) Process for the preparation of ziprasidone
CA2433720A1 (en) An improved process for preparing pure ondansetron hydrochloride dihydrate
WO2011004281A1 (en) A process for the preparation of amorphous form of rabeprazole sodium
JP5600597B2 (en) Compounds and methods for treating cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12726217

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12726217

Country of ref document: EP

Kind code of ref document: A1